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Mucopolysaccharidosis type VII (MPS VII, Sly syndrome) is a very rare lysosomal storage
disease caused by a deficiency of the enzyme β-glucuronidase (GUS), which is required for the
degradation of three glycosaminoglycans (GAGs): dermatan sulfate, heparan sulfate and
chondroitin sulfate. Progressive accumulation of these GAGs in lysosomes leads to increasing
dysfunction in numerous tissues and organs. Enzyme replacement therapy (ERT) has been used
successfully for other MPS disorders, but there is no approved treatment for MPS VII. Here we
describe the first human treatment with recombinant human GUS (rhGUS), an investigational
therapy for MPS VII, in a 12-year old boy with advanced stage MPS VII. Despite a tracheostomy,
nocturnal continuous positive airway pressure, and oxygen therapy, significant pulmonary
restriction and obstruction led to oxygen dependence and end-tidal carbon dioxide (ETCO2) levels
in the 60-80 mmHg range, eventually approaching respiratory failure (ETCO2 of 100 mmHg) and
the need for full-time ventilation. Since no additional medical measures could improve his
function, we implemented experimental ERT by infusing rhGUS at 2 mg/kg over 4 hours every 2
weeks for 24 weeks. Safety was evaluated by standard assessments and observance for any
infusion associated reactions (IARs). Urinary GAG (uGAG) levels, pulmonary function, oxygen
dependence, CO2 levels, cardiac valve function, liver and spleen size, and growth velocity were
assessed to evaluate response to therapy. rhGUS infusions were well tolerated. No serious adverse
events (SAEs) or IARs were observed. After initiation of rhGUS infusions, the patient's uGAG
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excretion decreased by more than 50%. Liver and spleen size were reduced within 2 weeks of the
first infusion and reached normal size by 24 weeks. Pulmonary function appeared to improve
during the course of treatment based on reduced changes in ETCO2 after off-ventilator challenges
and a reduced oxygen requirement. The patient regained the ability to eat orally, gained weight,
and his energy and activity levels increased. Over 24 weeks, treatment with every-other-week
infusions of rhGUS was well tolerated with no SAEs, IARs, or hypersensitivity reactions and was
associated with measurable improvement in objective clinical measures and quality of life.

Keywords
mucopolysaccharidosis type VII; enzyme replacement therapy; pulmonary function; physician
global impression of change; hepatosplenomegaly; Sly syndrome
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1.0 Introduction
Mucopolysaccharidosis type VII (MPS VII), also known as Sly Syndrome, is a very rare
form of MPS characterized by a deficiency of the lysosomal enzyme β-glucuronidase (EC
3.2.1.31), which is required for the degradation of three glycosaminoglycans (GAGs):
dermatan sulfate, heparan sulfate, and chondroitin sulfate [1-4]. Progressive accumulation of
these GAGs in lysosomes leads to increasing dysfunction in numerous tissues and organs.
MPS VII symptoms are varied and may include abnormally coarse facies,
hepatosplenomegaly, pulmonary disease, cardiovascular complications, joint stiffness, short
stature, and skeletal disease known as dysostosis multiplex [1]. Developmental delay may be
present in more severely affected MPS VII patients.
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No treatments are currently approved for MPS VII. Enzyme replacement therapy (ERT) has
been used successfully in the treatment of other lysosomal storage disorders in humans
including MPS I, MPS II, MPS IVA, and MPS VI [5-9]. In mouse models of MPS VII, ERT
with β-glucuronidase has been shown to reduce lysosomal storage of GAG and improve
behavior, auditory function, and skeletal dysplasia [10-12].
This report describes the results of the first human treatment with recombinant human βglucuronidase (rhGUS), an investigational therapy, in a 12-year-old child with advanced
stage MPS VII.

2.0 Materials and methods
2.1 Case description
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The patient was a 12-year-old boy with advanced stage MPS VII who was born at 35 weeks
gestation with hydrops fetalis and hepatosplenomegaly. At 18 months of age, the patient
presented with severe cord compression, and diagnosis of MPS VII by leukocyte and
fibroblast assay was made by a consulting geneticist (JF) at the time of a required cervical
fusion surgery. No β-glucuronidase enzyme activity was detected in fibroblasts and
negligible activity of 0.9 nmol/mg protein/hour (reference range, 250.5-883.1) was detected
in leukocytes. A mutation analysis in 2014 identified two mutations: S485F and W288L.
Neither mutation has been previously reported in the literature to our knowledge.
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Over the ensuing years, the patient's MPS VII disease progressed steadily. The patient had
learned to walk and attended school, but he lost the ability to walk in 2010 and needed a
tracheostomy due to upper airway obstruction. The patient had considerable progressive
heart valve disease and an enlarging liver and spleen, both of which compounded his
progressively worsening pulmonary status. In the year before rhGUS treatment, the patient
was hospitalized several times for respiratory failure and elevated end-tidal carbon dioxide
(ETCO2) levels of 80 mmHg or more. In September 2013, the patient was admitted again for
pulmonary failure. By October 2013, the patient had progressively worsening pulmonary
function leading to oxygen dependence and CO2 retention, and was close to pulmonary
failure. Management of this patient's poor pulmonary function using maximally available
treatment including tracheostomy, oxygen therapy, and full-time ventilation did not
sufficiently support his pulmonary function and no additional medical measures could
improve his pulmonary function. The patient was somnolent, relatively inactive during the
day due to fatigue, and had stopped attending school. He took all feeds via gastrostomy tube
(G tube). He was not considered likely to survive much longer if no new intervention was
provided.
An emergency request for compassionate use of investigational rhGUS therapy was made
and granted by the US Food and Drug Administration (FDA), and investigational rhGUS
was provided by the drug developer. The patient and his parents provided informed consent
to the treatment with rhGUS after a discussion of the potential risks and benefits of
treatment. After consenting, the patient was evaluated for clinical condition using standard
clinical assessments appropriate for his condition. Samples of urine and blood were taken to
assess his baseline biochemical condition and to provide control specimens for evaluation of
any immune response to rhGUS.
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2.2 Treatment and assessments
The patient was treated by intravenous (IV) infusions of 2 mg/kg of rhGUS (Ultragenyx
Pharmaceutical Inc., Novato, CA) administered over approximately 4 hours every 2 weeks,
for 24 weeks. At 6 weeks, 12 weeks, and 24 weeks, the patient was evaluated to determine
whether his condition and the benefits and risks compelled continued treatment with rhGUS.
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Safety was evaluated by assessing for any adverse events (AEs) during exposure to rhGUS
throughout the study by clinical laboratory measures and by noting the number and types of
infusion associated reactions (IARs). All AEs occurring from the onset of the infusion to
within four hours following the end of the infusion were considered as IARs. A preliminary
assessment of formation of antibodies to rhGUS was performed using a standard bridging
enzyme-linked immunosorbent assay (ELISA). Safety events were recorded in the patient's
medical record.
Total urinary GAG (uGAG) excretion (normalized to urinary creatinine concentration) was
evaluated in first morning void urine at baseline and weeks 2, 4, 6, 8, 10, 12, 18, and 24
using the nonreducing ends (NRE) method (ARUP Laboratories, Salt Lake City, Utah,
USA) [13]. Other measures of efficacy were evaluated at baseline and weeks 12 and 24.
These measures included pulmonary function assessed by CO2 retention level (ETCO2) and
pulse oximetry; cardiac mass evaluated by echocardiogram and scored as a z score relative
Mol Genet Metab. Author manuscript; available in PMC 2016 February 01.

Fox et al.

Page 4

Author Manuscript

to normal ventricular mass; liver and spleen size evaluated by ultrasound and clinical exam;
weight; length; and a physician global impression of change scale (PGI-C). To score the
PGI-C, the physician caring for the patient provided a global assessment of change using a
7-point scale ranging from -3 (significant worsening) to +3 (significant improvement) [14].
The overall score was based on reported changes in a list of disease-specific abnormalities
projected to respond to treatment. An institutional review board approved the study. This
report provides results from the first 24 weeks of treatment and the study is ongoing.

3.0 Results
3.1 Patient History
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The MPS VII patient presented with progressive worsening of pulmonary insufficiency with
worsening CO2 retention of 80 mmHg or higher that was not sufficiently supported by
maximally available medical treatment. Based on his clinical condition and progression at
that time, ERT with investigational rhGUS represented this patient's only available option
for potential improvement. Thus, an emergency request for compassionate use of
investigational rhGUS therapy was made and granted by the FDA and investigational
rhGUS was provided by the drug developer.
3.2 rhGUS Infusions
The patient was treated with IV infusion of 2 mg/kg of rhGUS every other week. A total of
12 infusions were received with one missed infusion at week 16 due to an intercurrent
illness of respiratory infection with fever (Table 1). At week 24, the total dose administered
was increased from 50 mg to 60 mg to account for an increase in the patient's weight (see
section 3.4.5).
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At 30 to 60 minutes before each infusion, the patient was pretreated with an antihistamine
medication, cetirizine hydrochloride, 7.5 mg per G tube. Within 24 hours after the first and
second infusions, the patient experienced a non-pruritic erythematous rash on his chest that
resolved or improved with hydroxyzine administration. The hydroxyzine became a routine
post-infusion prophylactic for 24 hours after the infusion beginning with the third infusion.
Post infusion hydroxyzine was ended after Week 32 without further hive-like rash observed.
Initially, no antipyretic medication was provided but, beginning on the eighth infusion,
ibuprofen (200 mg) was also administered prophylactically. The addition was due to a fever
experienced after an infusion, although the fever was later determined to be due to an
intercurrent illness.
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After the first 4 infusions, some fatigue was noted for the day after the infusion. Based on
experiences with other MPS diseases, it was speculated that fluid overload from the saline
load of the infusion may be a problem due to the patient's advanced heart valve disease.
Beginning with the fifth infusion, the patient received a single 10 mg dose of diuretic
(furosemide) per G tube after each infusion. The diuretic reduced his fatigue the day after
infusions and was therefore continued prophylactically after subsequent infusions.
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Adverse events occurring during 24 weeks of study that were considered possibly related to
rhGUS treatment are shown in Table 2.
No serious adverse events (SAEs) or hospitalizations and no IARs or hypersensitivity
reactions were observed during the 24 weeks of treatment. Serum was collected for
preliminary assessment of antibodies against rhGUS by ELISA. Background signal was
detected in baseline samples, but no increase in signal was observed at 12 or 24 weeks. The
assay is still being optimized.
3.4 Efficacy
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3.4.1 uGAG Levels as a measure of lysosomal storage—Experience in 4 MPS
diseases and prior work in animal models suggests that uGAG excretion corrected for
creatinine concentration can provide a reasonable assessment of lysosomal storage in MPS
diseases. At baseline, the patient's uGAG level as measured by the NRE method was 2.36
mg/mmol creatinine. Urinary GAG levels decreased rapidly upon treatment with rhGUS
with a reduction of 59.1% from baseline observed at 2 weeks (Figure 1). A maximum
reduction in uGAG of 74.6% from baseline was observed at 6 weeks; levels stabilized
thereafter, with reductions of approximately 55%-65% from baseline.
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3.4.2 Pulmonary Function—Prior to his initial infusion with rhGUS, the patient had
substantial CO2 retention as measured by ETCO2 testing and had pulmonary insufficiency
bordering on pulmonary failure. He had begun receiving continuous ventilator support via
his tracheostomy. After his second hospitalization for pulmonary distress, the ventilator
synchronized intermittent mandatory ventilation (SIMV) rate was set at 18; it had been
reduced to a rate of 12 but attempts to further decrease the rate to 10 were unsuccessful, and
the patient could not tolerate 1-hour periods off the ventilator without ETCO2 levels rising
to more than 80 mmHg. At the time of the initial rhGUS infusion, the patient's ventilator
settings were SIMV rate 12, tidal volume 200, pressure support 10, and fraction of inspired
oxygen (FIO2) 35%. On this setting, his ETCO2 ranged from the high 40s to low 50s
mmHg.
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Following rhGUS treatment, pulmonary function appeared to improve as the patient's liver
and spleen size declined rapidly after a single dose, and then it reached a plateau. After 13
weeks of treatment (7 infusions), the patient was challenged with 1-hour periods off the
ventilator. Pre- and post-challenge ETCO2 levels are shown in Figure 2. Initially, the patient
had large increases (10 mmHg or more) in ETCO2 after 13-16 weeks of treatment and could
not tolerate being off the ventilator. After 20 weeks of treatment, significantly smaller
increases or no changes in post-challenge ETCO2 levels wereobserved. In addition, after 24
weeks of treatment, the patient tolerated periods of 80 minutes 2 times per day for total of
160 minutes per day off the ventilator without an increase in ETCO2 from an initial 53
mmHg. By week 24, supplemental oxygen had been successfully weaned to 28% from the
previously noted 35% oxygen requirement.
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3.4.3 Cardiac function—The patient underwent a transthoracic echocardiogram
approximately 2 months before starting rhGUS therapy; this is considered the baseline
cardiac measure for this study. At that time, there was mild mitral valve regurgitation,
abnormal aortic valve with insufficiency, and a dilated aortic root. Hyperdynamic left
ventricular shortening fraction, asymmetric septal hypertrophy, and diastolic dysfunction
were observed; there was no pericardial effusion. Left ventricular (LV) mass was measured
at 141.38 g and a LV mass index of 150.36 g/height2.7. As noted in section 3.2, these valve
and heart function problems were sufficient to provide some difficulty with fluid overload
after the infusions, necessitating the addition of furosemide treatment post infusion, which
helped reduce post-infusion fatigue. A repeat transthoracic echocardiogram at week 14 prior
to the patient's eighth infusion revealed no changes. LV mass and LV mass index were not
assessed at week 14.
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A baseline electrocardiogram (ECG) showed the QRS axis to be 43 degrees and ST at a rate
of 123 beats per minute (bpm). Bi-atrial and left ventricular hypertrophy were present but
there were no important ST-T changes and all intervals were normal. A repeat ECG at Week
14 showed the QRS axis to be 68 degrees and normal sinus rhythm of 105 bpm. No atrial
hypertrophy was present; in addition, there were no ST-T changes and all intervals were
normal. Possible biventricular hypertrophy was still noted.
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3.4.4 Hepatosplenomegaly—The size of the patient's liver and spleen was estimated
clinically and by using ultrasound but an accurate estimate of volume could not be obtained
by ultrasound due to unusual anatomy. By clinical examination at baseline, his liver size was
extremely large at 2 cm below the umbilicus and his spleen tip extended into his groin
(Table 3). At 2 weeks after the first infusion, both his liver and spleen size had decreased
substantially. By 24 weeks, liver and spleen size appeared normal, a finding confirmed by
ultrasound.
3.4.5 Growth—Prior to rhGUS infusions, the patient had limited interest in pleasure
feedings and was aspirating food. Pleasure feedings were done by the patient's mother
generally after regular nourishment through his G tube.
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After infusions, the patient's appetite increased and the patient asked for more food from the
staff. A swallow exam performed after 19 weeks of treatment showed the patient was no
longer aspirating food. As significant, unexpected weight gain was also noted, his
supplemental gastrostomy feedings were decreased to twice per day prior to breakfast and
lunch only, leading to some loss of weight in the last period as noted in Figure 3.
Supplements were changed in relationship to new dietary changes. The patient continues to
tolerate oral feedings with supplemental gastrostomy intake. In July 2014, after
approximately 38 weeks of treatment, a repeat modified barium study was done. While he
continues to be a significant aspiration risk with thin liquids, he was noted to safely tolerate
thickened liquids, solids, and purees allowing expansion of his dietary intake.
Patient length measured as standing height was difficult to obtain due to lack of walking and
weight bearing. Supine length was 110 cm at the start of infusions and did not change during
24 weeks of study.
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3.4.6 Physician Global Impression of Change—The patient's primary physician
noted general improvements in health after initiation of rhGUS infusions. Key findings
included less fatigue and increased stamina; increased school attendance; and independent
manipulation of his wheelchair, which the patient had not done for the previous two years.
For the PGI-C, a set of clinical problems were identified at baseline and assessed at 12 and
24 weeks using a 7-point score (Table 4). At both weeks 12 and 24, the patient had an
overall score of +2, indicating moderate improvement overall.

4.0 Discussion
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This report presents findings from the first-in-human treatment with investigational rhGUS
ERT in a 12-year-old patient with MPS VII. Over 24 weeks, treatment with every-otherweek infusions of rhGUS was well tolerated with no SAEs, IARs, or hypersensitivity
reactions and with measurable improvement in objective clinical measures and quality of
life.
After initiation of rhGUS infusions, the patient's liver and spleen rapidly reduced in size, and
his urinary GAG excretion decreased by more than 50%, a reduction similar to that observed
in studies of ERT for other MPS disorders [7, 8]. Pulmonary function appeared to improve
somewhat during the course of treatment. After 16 weeks of rhGUS therapy, the patient
could begin to tolerate brief off-ventilator challenges with smaller increases in ETCO2
observed as the study went on, but ventilator support was not withdrawn. No significant
changes in cardiac function were noted.
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rhGUS treatment significantly enhanced the patient's quality of life. Since the initiation of
the infusion protocol, the patient showed marked improvement in his energy level as
manifested by his ability to participate in school and recreational activities, and decreased
daytime sleeping. He also recovered some expanded use of his upper extremities with the
ability to pronate and point, allowing use of electronic devices for entertainment and remote
interaction with his mother and manipulation of his wheelchair. The patient also became
more interested in pleasure feeding. Whereas he was aspirating food at the beginning of the
study, the return of a safe swallow reflex allowed him to begin oral feedings again, and by
24 weeks his nutrition was significantly supported by his oral intake. The hospital staff
noted the patient's increased appetite and described him as being “constantly hungry”.
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rhGUS infusions were generally well tolerated. The patient did not have any hypersensitivity
reactions or IARs and no immune response has yet been documented. Observations of rash
and fluid overload after the first few infusions led to prophylactic implementation of
antihistamine and furosemide with subsequent infusions, which minimized these effects.
Overall, the patient has improved on rhGUS ERT with a reduction in lysosomal storage and
increased energy and activity levels. He is able to eat orally and his pulmonary function has
improved clinically, but he still remains a child with significant health issues. The rhGUS
infusions have been well tolerated and study is ongoing to assess the outcomes of further
treatment.
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AE

adverse event

bpm

beats per minute

CO2

carbon dioxide

CPAP

continuous positive airway pressure

CTCAE

common terminology criteria for adverse events

Desat

desaturation

ECG

electrocardiogram

ECHO

echocardiogram

ELISA

enzyme-linked immunosorbent assay

ERT

enzyme replacement therapy

ETCO2

end-tidal carbon dioxide

FDA

Food and Drug Administration

FIO2

fraction of inspired oxygen

GAG

glycosaminoglycans

G tube

gastrostomy tube

GUS

glucuronidase

HCl

hydrochloride

IAR

infusion associated reaction

kg

kilogram

LV

left ventricle

mg

milligram

mmHg

millimeters of mercury

mmol

millimole

MPS

mucopolysaccharidosis

MPS I

mucopolysaccharidosis type I
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MPS II

mucopolysaccharidosis type II

MPS IVA

mucopolysaccharidosis type IVA, Morquio A Syndrome

MPS VI

mucopolysaccharidosis type VI

MPS VII

mucopolysaccharidosis type VII

NRE

non-reducing ends

PGI-C

physician's global impression of change

rhGUS

recombinant human glucuronidase

SAE

serious adverse event

SIMV

synchronized intermittent mandatory ventilation

Temp

temperature

uGAG

urinary glycosaminoglycan

US

United States
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Highlights
•

rhGUS is an experimental enzyme replacement therapy for
mucopolysaccharidosis type VII

•

We report the first human use of rhGUS in a patient with advanced stage MPS
VII

•

rhGUS infusions were generally well tolerated

•

Indicators of lysosomal storage decreased within 2 weeks of treatment initiation

•

Positive treatment effects also observed for pulmonary function and quality of
life
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Figure 1. Urinary GAG During Infusions With rhGUS

Urinary GAG as measured by the NRE method over 24 weeks of study is expressed as
absolute levels (mg/mol creatinine) (A) and relative percent of baseline (B)
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Figure 2. Comparison in ETCO2 Before and After the Off-Ventilator Challenge

Off-ventilator challenges began after 13 weeks of rhGUS treatment. Changes in ETCO2 (in
mmHg) before and after the off-ventilator challenge at each timepoint measured are shown.
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Figure 3. Weight Growth During Treatment with rhGUS

Patient weight as measured in kg over 24 weeks of study is shown. Supplemental
gastrostomy feedings were reduced after 19 weeks leading to reduction in weight gained.
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Baseline

50 mg

Week

Dose
(2 mg/kg)
50 mg

2

1

50 mg

4

3

50 mg

6

4

50 mg
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5

50 mg
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6
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50 mg
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50 mg
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5

5

7

7

8

8

-

11

12

12

8

12

12

14

14

16

22

24

24

3

4

8

1

Baseline

4

1

Baseline

6

Infusion

2 days

1 day

10 days

16 days

11 days

11 days

1 day

1 day

1 day

same day

7 days

1 day

5 days

1 day

Time from Last Infusion to Start of AE

<1 day

4 days

1 day

3 days

2 days

2 days

4 days

1 day

2 days

1 day

1 day

7 days

1 day

1 day

Duration of AE

Increased Temp

Fatigue

Increased ETCO2 and emesis

Increased Secretions and Desat

Increased Secretions and Desat

Elevated temp and heart rate

Blood-tinged secretions & Desat

Elevated temp and heart rate

Desat, Fever Increased secretions

Increased ETCO2

Increased ETCO2

Increased ETCO2

Coarse rales, non-productive cough and requires suction

Non pruritic erythematous rash

Adverse Event

1

1

1

2

2

1

2

1

1

1

1

1

1

1

CTCAE Severitya

carbon dioxide; desat, desaturation; temp, temperature

Common Terminology Criteria for Adverse Events (CTCAE) Severity: 1=Mild, 2= Moderate, 3=Severe/undesirable, 4=Life threatening/ debilitating, 5=Death; AE, adverse event; ETCO2, end-tidal

a

Author Manuscript

Week

Author Manuscript
Table 2

Author Manuscript

Adverse Events Considered Possibly Related to rhGUS Treatment

Fox et al.
Page 16

Mol Genet Metab. Author manuscript; available in PMC 2016 February 01.

Fox et al.

Page 17

Table 3

Liver and Spleen Size by Clinical Examination

Author Manuscript

Weeks

Liver

Spleen

Pre-treatment

∼2 cm below umbilicus

Extended into groin

2

∼1 cm above umbilicus

At umbilicus

8

∼1 cm above umbilicus

At umbilicus

12

Above umbilicus

Above umbilicus

24

3.5 cm above umbilicus
(2cm below costal margin)

Palpable spleen tip
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Table 4

PGI-C Score as assessed by characterization of specific MPS clinical findings
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BASELINE
MPS PHYSICAL FINDINGS

Present

Not Present

Week 12

Week 24

Short stature/slow growth rate

Y

0

0

Limited visual acuity/difficulty reading plain text

Y

0

0

0

0

Frequent infections (ear, respiratory, sinus)

Y

Author Manuscript

Limited endurance/fatigue/lack of “energy”/malaise

Y

1

1

Short of breath/difficulty breathing on exertion

Y

1

1

Diminished pulmonary function

Y

1

1

Respiratory support needed (tracheostomy, BiPAP, CPAP, supplemental O2)

Y

1

1

Diminished walking ability (joint stiffness, contractures)

Y

0

0

Assistive walking devices needed (walker, AFOs, wheelchair etc.)

Y

0

0

Difficulty with transfers (up from chair or floor, in/outof bed, tub, car)

Y

0

0

Difficulty bending over due to enlarged abdomen

Y

1

1

Poor appetite (limited desire and difficulty eating)

Y

2

1

2

2

Overall Score

Entry Codes:
N = New Finding

0= No Change

-1 = Mild Worsening

+1 = Mild Improvement

-2 = Moderate Worsening

+2 = Moderate Improvement

-3 = Significant Worsening +3 = Significant Improvement
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